Will These 3 Health-Care Doubles Keep Running?
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics around the investing world.
In this series, David takes a look at three health-care stocks that have doubled and examines whether they can keep it going for the rest of the year. Today's edition features Pharmacyclics, with BTK inhibitor ibrutinib, Affymax, which recently received approval for Omontys, and the ongoing march of XOMA's 052 drug candidate through clinical trials. Can these stocks keep running? Watch and find out.
Health-care investors are always looking for the next big breakthrough. Motley Fool co-founder David Gardner recently identified a small-cap health-care company that he believes is poised for monster returns. To uncover this top pick today, enjoy the special free report "Discover the Next Rule-Breaking Multibagger." Don't miss out on this limited-time offer and your opportunity to discover this game-changing company before the market does. Click here to access your report -- it's totally free.
At the time this article was published David Williamsonand The Motley Fool own shares of Johnson & Johnson.Motley Fool newsletter services recommendJohnson & Johnson. Try any of our Foolish newsletter servicesfree for 30 days. We Fools don't all hold the same opinions, but we all believe thatconsidering a diverse range of insightsmakes us better investors. The Motley Fool has adisclosure policy.
Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.